Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy

Sponsor
Seoul St. Mary's Hospital
Study ID
NCT01360151
Status
Unknown

Conditions

  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
45 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

This is a prospective, comparative control analysis. The investigators want to evaluate the aqueous humor levels of vascular endothelial growth factor in polypoidal choroidal vasculopathy and the effect of photodynamic therapy and combination treatment of photodynamic therapy and Lucentis (Ranibizumab)on the level of vascular endothelial growth factor.

Key Dates

Start date
Feb 28, 2011
Status verified
Apr 2011
Primary completion
May 31, 2011
Completion
May 31, 2011

Study Design

Enrollment
16 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: experimental
    Arm 1 : combination treatment of ranibizumab(Lucentis) and verteporfin(Visudyne) injection
  • Active Comparator: active comparator
    Arm 2 : Treatment of verteporfin(Visudyne)
  • No Intervention: normal control group
    Arm 3 : normal control group

Primary Outcome Measure

change from baseline in cytokine levels at 1 week, 1 month and 3 month [ Time Frame: baseline, 1 week, 1 month, 3 month ]

Related Studies